Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.OncoGenex Technologies has announced that the updated Phase II data on the company's lead cancer drug candidate, OGX-011, also referred to as custirsen, revealed encouraging outcomes in the treatment of patients with hormone refractory prostate cancer.
Subscribe to our email newsletter
Overall, custirsen was well-tolerated in combination with either docetaxel or mitoxantrone administered as second-line chemotherapy in patients with hormone refractory prostate cancer. Custirsen was associated with durable pain responses in 50% or more of patients, a minimum of a 50% PSA decline in 27% or more of patients, and better than expected survival with 60% of patients alive at a median follow-up of 13.3 months.
This study was designed as an open-label, randomized, multicenter study evaluating weekly administration of custirsen in combination with second-line chemotherapy in patients with metastatic hormone refractory prostate cancer who were previously treated with a minimum of two cycles of docetaxel-based first-line chemotherapy. Patients in this study represented a poor prognostic population due to rapid disease progression after completing first-line docetaxel therapy.
Clinical studies that will support product approval are being planned utilizing chemotherapy plus custirsen as second-line therapy in patients progressing after a first-line docetaxel regimen.